1,431 Shares in United Therapeutics Corporation (NASDAQ:UTHR) Purchased by S&CO Inc.

Key Points

• S&CO Inc. acquired a new stake in United Therapeutics Corporation, purchasing 1,431 shares valued at approximately $441,000 during the 1st quarter.
• Institutional investors collectively own 94.08% of United Therapeutics stocks, with notable increases in holdings from Allianz Asset Management and other firms.
• Analysts have adjusted their price targets for United Therapeutics, with estimates ranging from $330 to $425, reflecting mixed sentiments on the stock's performance.

S&CO Inc. purchased a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 1,431 shares of the biotechnology company's stock, valued at approximately $441,000.

Several other large investors have also modified their holdings of the stock. Dunhill Financial LLC increased its holdings in shares of United Therapeutics by 100.0% in the 4th quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company's stock valued at $35,000 after purchasing an additional 50 shares in the last quarter. Sound Income Strategies LLC acquired a new position in United Therapeutics in the first quarter worth $49,000. State of Wyoming acquired a new position in shares of United Therapeutics during the fourth quarter valued at $62,000. Curat Global LLC bought a new stake in United Therapeutics in the first quarter worth about $63,000. Finally, Natixis acquired a new stake in United Therapeutics during the 4th quarter worth about $85,000. Institutional investors and hedge funds own 94.08% of the company's stock.

Insiders Place Their Bets

In other news, Director Richard Giltner sold 3,036 shares of the business's stock in a transaction that occurred on Tuesday, June 24th. The stock was sold at an average price of $289.60, for a total value of $879,225.60. Following the sale, the director directly owned 19,384 shares of the company's stock, valued at $5,613,606.40. The trade was a 13.54% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Paul A. Mahon sold 11,000 shares of the business's stock in a transaction that occurred on Thursday, July 24th. The stock was sold at an average price of $304.11, for a total transaction of $3,345,210.00. Following the completion of the transaction, the executive vice president owned 36,781 shares of the company's stock, valued at approximately $11,185,469.91. The trade was a 23.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 81,681 shares of company stock valued at $24,628,589 over the last three months. Company insiders own 10.30% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. JPMorgan Chase & Co. reduced their target price on United Therapeutics from $350.00 to $330.00 and set an "overweight" rating for the company in a report on Tuesday, July 8th. Cantor Fitzgerald started coverage on United Therapeutics in a research report on Monday, June 2nd. They issued an "overweight" rating and a $405.00 target price on the stock. HC Wainwright reiterated a "buy" rating and set a $425.00 target price on shares of United Therapeutics in a research note on Monday, May 5th. Bank of America dropped their price target on United Therapeutics from $321.00 to $315.00 and set a "neutral" rating for the company in a report on Wednesday, June 11th. Finally, Wells Fargo & Company reissued an "equal weight" rating and set a $314.00 price target (down previously from $395.00) on shares of United Therapeutics in a report on Friday, April 25th. Four investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $383.08.

United Therapeutics Stock Performance

Shares of United Therapeutics stock traded down $0.58 on Tuesday, hitting $297.56. The company had a trading volume of 527,065 shares, compared to its average volume of 369,896. The stock has a 50 day moving average of $299.63 and a 200-day moving average of $314.91. United Therapeutics Corporation has a 1 year low of $266.98 and a 1 year high of $417.82. The stock has a market capitalization of $13.42 billion, a price-to-earnings ratio of 11.87, a P/E/G ratio of 6.50 and a beta of 0.53.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share for the quarter, beating analysts' consensus estimates of $6.29 by $0.34. The business had revenue of $794.40 million for the quarter, compared to the consensus estimate of $726.82 million. United Therapeutics had a return on equity of 19.33% and a net margin of 40.44%. The company's revenue for the quarter was up 17.2% on a year-over-year basis. During the same quarter last year, the business posted $6.17 earnings per share. Equities analysts anticipate that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.